IRCCS San Martino University Hospital, Largo R. Benzi, 10, 16132 Genova, Italy.
European and Italian Patent Attorney, Marchi & Partners S.r.l., Via V. Pisani 13, 20124 Milan, Italy.
J Med Chem. 2023 Apr 13;66(7):4532-4547. doi: 10.1021/acs.jmedchem.3c00148. Epub 2023 Apr 3.
Technetium-99m is the workhorse of diagnostic nuclear medicine. The aim of the work is to analyze the technetium-99m patents since 2000 to photograph its innovation. QUESTEL's ORBIT Intelligence system was used for the collection of technetium inventions disclosed in patents and patent applications in more than 96 countries in the period 2000-2022; 2768 patent documents were analyzed. Patent counting and analysis have shown that SPECT imaging using technetium-99m radiopharmaceuticals is still robust. The introduction of new technetium-99m radiopharmaceuticals into clinical routine goes beyond successful trials. In eastern economies, such as China and other emerging markets, patent applications are on the rise, while those in developed western countries are stagnating, with some exceptions for the United States. But despite the difficulties, academic and industrial research on these tracers remains essential for the development of nuclear medicine.
锝-99m 是诊断核医学的主力。这项工作的目的是分析自 2000 年以来的锝-99m 专利，以观察其创新情况。QUESTEL 的 ORBIT 情报系统用于收集 2000-2022 年期间来自 96 个以上国家的专利和专利申请中披露的锝发明；分析了 2768 份专利文件。专利计数和分析表明，使用锝-99m 放射性药物的 SPECT 成像仍然很强大。新的锝-99m 放射性药物引入临床常规已不仅仅是成功的试验。在东方经济体，如中国和其他新兴市场，专利申请正在增加，而在发达的西方国家，专利申请则停滞不前，美国也有一些例外。但尽管存在困难，对这些示踪剂的学术和工业研究对于核医学的发展仍然至关重要。
